STRUCTURE-FUNCTION RELATIONSHIP, REGULATION AND GENETIC VARIATION IN HIGH DENSITY LIPOPROTEINS: PROSPECTS FOR THE PREVENTION AND THERAPY OF CORONARY ARTERY DISEASE

Abstract: 

High-density lipoprotein (HDL) is an attractive target for preventing and curing coronary artery disease (CAD) in view of the inverse association between plasma HDL cholesterol and CAD risk as well as the multiple anti-atherogenic properties of HDL. HDL composition and functionality are affected by various factors but the association of specific HDL particles with CAD risk is currently unknown. All these reasons necessitate the search for proper biomarkers to assess and monitor HDL-related CAD risk.

The goal of current HDL-based therapies are not merely to increase HDL cholesterol levels but generate HDL particles with desired biological properties that confer protection from cardiovascular disease. As yet, no effective HDL-tailored therapy of CAD is available.

This proposal aims to establish a scientific network dedicated to study HDL physiology, to identify new targets for HDL-based therapies and to discover biomarkers which can be used for diagnosis, prevention and therapy of CAD.

The Workpackages (WPs) of the proposed study are:

  • WP1: to elucidate the signal transduction pathways that mediate the atheroprotective functions of HDL in endothelial cells;
  • WP2-WP4: to identify new genes and miRNAs involved in HDL biogenesis and functions via high throughput genomic studies;
  • WP5-WP6: to correlate changes in the HDL structure with its functions in animal models and in human subjects with abnormally high or low HDL levels;
  • WP7: to study the genetic variation of genes that are involved in HDL biogenesis and metabolism in the Greek population.

It is expected that the proposed study will identify novel molecules that could be used as biomarkers for diagnosis as well as targets for future HDL-based therapies, will provide new knowledge on the heterogeneity of plasma HDL in the healthy population as well as in patients with CAD and will suggest therapies that restore the size and the functions of the HDL subpopulations.

Project info

Acronym:
HDLbio-therapies
Coordinating Institution:
University of Crete
Scientific Coordinator:
Kardassis Dimitris
Research Team 2 Leader:
Chroni Angelika
Research Team 3 Leader:
Rallidis Loukianos

Stats

I.D.:
1220
Mis:
377286
Duration (months):
45
Budget:
599 400.00
Diavgeia:
ΑΔΑ: Β4ΛΔ9-Ω2Ο

News